Article Information
History
- February 24, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Wei Wang1,
- Emilie Goguet2,
- Stephanie Paz Padilla1,
- Russell Vassell1,
- Simon Pollett3,4,
- Edward Mitre2,* and
- Carol D. Weiss1,*,†
- 1Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
- 2Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
- 3Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
- 4Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America
- ↵†Corresponding author:
Carol D. Weiss, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, 20993; email: carol.weiss{at}fda.hhs.gov.
↵* These authors contributed equally.
Posted February 24, 2023.
Bivalent COVID-19 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens
